Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06686771 · ClinicalTrials.gov registry record · Phase 3
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Canadian Cancer Trials Group.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 320
- Enrollment target
- 20
- Study locations
NCT06686771: Recruiting Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Canadian Cancer Trials Group.
NCT06686771 is a Phase 3 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by Canadian Cancer Trials Group. The registered enrollment target is 320 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06686771, a Phase 3 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Canadian Cancer Trials Group.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 320 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approach is better or worse than the usual approach for lung cancer. The usual approach is defined as the care most people get for non-small cell lung cancer.
Conditions Studied
Interventions
- RADIATION SBRT
- OTHER First or second-line standard of care therapy
Study Locations (20)
Illinois
- Alton Memorial Hospital - Alton
- Northwestern University - Chicago
- Decatur Memorial Hospital - Decatur
- Northwestern Medicine Cancer Center Kishwaukee - DeKalb
- Crossroads Cancer Center - Effingham
- Northwestern Medicine Cancer Center Delnor - Geneva
- Northwestern Medicine Glenview Outpatient Center - Glenview
- Northwestern Medicine Grayslake Outpatient Center - Grayslake
- Northwestern Medicine Lake Forest Hospital - Lake Forest
- HSHS Saint Elizabeth's Hospital - O'Fallon
- Northwestern Medicine Oak Brook - Oak Brook
- Northwestern Medicine Orland Park - Orland Park
- Memorial Hospital East - Shiloh
Idaho
- Saint Luke's Cancer Institute - Boise - Boise
- Saint Luke's Cancer Institute - Fruitland - Fruitland
- Saint Luke's Cancer Institute - Meridian - Meridian
- Saint Luke's Cancer Institute - Nampa - Nampa
California
- City of Hope Comprehensive Cancer Center - Duarte
- City of Hope at Irvine Lennar - Irvine
Colorado
- Saint Mary's Hospital and Regional Medical Center - Grand Junction
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2025-12-16 |
| Est. Completion | 2030-12-31 |
| Phase | Phase 3 |
What NCT06686771 shows while recruiting
NCT06686771 is an interventional study that assigns participants to a tested intervention. The registered 320 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which SBRT is the first listed.
NCT06686771 names 20 study sites across 4 states, led by Illinois, Idaho, California.
Frequently Asked Questions
What is clinical trial NCT06686771 about?
NCT06686771 is a clinical study titled "Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer". This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approach is better or worse than the usual approach for lung cance...
What is the current status of trial NCT06686771?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 320 participants. The study started on 2025-12-16. Estimated completion is 2030-12-31.
What conditions does trial NCT06686771 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT06686771?
The interventions under investigation include: SBRT (RADIATION), First or second-line standard of care therapy (OTHER).
Who is sponsoring clinical trial NCT06686771?
This trial is sponsored by Canadian Cancer Trials Group, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06686771 being conducted?
This trial has 20 study locations across California, Colorado, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06686771's enrollment target sits among peer trials
320 114th of 454 higher than 339 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
- NCT04606446 · 320 participants · Phase 1
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI